Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies-Reference-Cited by-同舟云学术

Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies

Published:2023-04 Issue:4 Volume:29 Page:228-239
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Nikiforow Sarah,Frigault Matthew J.,Frey Noelle V.,Gardner Rebecca A.^ORCID,Komanduri Krishna V.,Perales Miguel-Angel^ORCID,Kebriaei Partow,Warkentin Phyllis Irene,Pasquini Marcelo,Aho Joy Lynn,Levine Bruce L.,Heslop Helen E.^ORCID,Hlucky Tracey L.,Habucky Karen,Gharibo Mecide,Jagasia Madan,Locke Frederick L.^ORCID

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference42 articles.

1. Moffitt Immunotherapy Working Group, Immune Cell Therapy (ICE-T) Program. Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap;Locke;J Immunother Cancer,2017

2. ASTCT Committee on Practice Guidelines survey on evaluation & management of diffuse large B-cell lymphoma after failure of chimeric antigen receptor T cell therapy (CAR-T) therapy;Ahmed;Transplant Cell Ther,2022

3. Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American Society for Transplantation and Cellular Therapy;Perales;Transplant Cell Ther,2022

4. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma;Munshi;Bone Marrow Transplant,2021

5. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy;Jain;Biol Blood Marrow Transplant,2019

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk-Based Qualification of Cellular Starting Material Collection Sites: Tools to Determine Scope of Manufacturer Audits and Reduce Duplicative Efforts;Transplantation and Cellular Therapy;2024-09

2. High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy;Journal of Clinical Medicine;2024-08-13

3. Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers;Cytotherapy;2024-08

4. Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products;Cytotherapy;2024-07

5. Development of a Safety Surveillance Plan for the Academic Medicine Sponsor Performing First-in-Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy;Transplantation and Cellular Therapy;2024-05